Scarica l'app Stockscreener
7.12
6.91%
0.46
Dopo l'orario di chiusura:
7.25
0.13
+1.83%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade
Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - tradingview.com
Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
ADIL Should I Buy - Intellectia AI
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn
Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 46.85% Positive SurpriseCash Flow Report - Vinanet
Adial Pharmaceuticals Acquires Azora Therapeutics in Stock-and-Preferred Deal - Minichart
Adial Pharmaceuticals announces annual shareholder meeting - Bitget
Form 8K Adial Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals (NASDAQ: ADIL) outlines Azora merger, heavy dilution and $53M share overhang - Stock Titan
Adial Pharmaceuticals Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support LevelProfitability Factor - dars.gov.et
Adial Pharmaceuticals Price Target Announced at $11.00/Share by Alliance Global Partners - Moomoo
Adial Pharmaceuticals Initiated at Buy by Alliance Global Partners - Moomoo
A. G. P. Initiates Adial Pharmaceuticals(ADIL.US) With Buy Rating, Announces Target Price $11 - moomoo.com
ADIL Q1 2026 Earnings: EPS Beats Estimates Sharply, But Revenue Remains AbsentRevenue Growth Outlook - vinanet.vn
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Fuels 4.44% Share UptickFinancial Data - Vinanet
Adial Pharmaceuticals Inc (ADIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adial Pharmaceuticals Inc (ADIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey
Adial Pharmaceuticals Inc (ADIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADIL|Adial Pharmaceuticals Inc|Price:2.860|Chg%:+0.080 - TradingKey
Adial Pharmaceuticals Inc (ADIL) Cash Flow - tradingkey.com
ADIL|Adial Pharmaceuticals Inc|Price:4.400|Chg%:+0.090 - TradingKey
Adial Pharmaceuticals, Inc Revenue Breakdown – NASDAQ:ADIL - TradingView
ADIL Q1 2026 Earnings: EPS Surprise Beat Amid Ongoing Clinical DevelopmentRevenue Guidance Update - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 1.09% as Stock Tests Key Support ZoneExhaustion Gap - dars.gov.et
Adial Pharmaceuticals (ADIL) Edges Higher as Shares Test Key Resistance ZoneVolume Profile - dars.gov.et
Adial Pharmaceuticals (ADIL) Slides 3.57%: Testing Key Support Near $2.56Accumulation Line - dars.gov.et
ADIL Q1 2026 Earnings: Better-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue StageTangible Book Value - vinanet.vn
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com South Africa
Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock By Investing.com - Investing.com Nigeria
Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock - Investing.com
Coastlands Capital (NASDAQ: ADIL) buys 3,233 ADIAL shares in open market - Stock Titan
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):